A s a steroid hormone, estrogen has been extensively investigated in various physiological and pathological functions and in carcinogenesis. We previously demonstrated that estrogen promotes the secretion of MICA/B through ADAM17, which helps lung cancer cells evade NKG2D-mediated immune surveillance. 1 Estrogen receptor α (ERα) and ERβ are two high-affinity nuclear receptors of estrogen that promote cancer by activating multiple growth factors and inhibiting tumorsuppressor genes. 2 Anti-estrogen therapy targeting the ER has been successfully used to treat ER-positive breast cancers. ER antagonists have been widely accepted in clinical practice as an effective treatment for breast tumors and a subset of ovarian cancers. 3 However, for some ovarian cancer patients, anti-estrogen therapy is not suitable. Most studies have exclusively focused on ER pathways and have ignored the interaction between estrogens and other immune cells in the tumor microenvironment.
Myeloid-derived suppressor cells (MDSCs) constitute a heterogeneous group of immune cells from the myeloid lineage. MDSCs were originally described as suppressors of T cells, particularly CD8+ T cells and have been confirmed to have critical roles in diseases, such as cancers and autoimmune disorders. Regarding the relationship between estrogen and MDSCs, it has been demonstrated that estrogens can promote the development of different estrogen-insensitive tumors by mobilizing MDSCs and enhancing their inhibitory functions via ERα signaling, which is independent of the direct effects of estrogens on tumor cells. 4 Estrogen signaling activates the signal transducer and activator of transcription factor 3 pathway in bone marrow myeloid precursors by enhancing Janus-activated kinase 2 and SRC activity, resulting in increased numbers of both myelomonocytic MDSCs and granulocytic MDSCs in tumor-bearing mice. A similar study showed that estrogens promote the progression of ER-negative breast cancer through the accumulation of MDSCs in the tumor microenvironment. 5 The significant effects of estrogens on antitumor immunity and tumor-promoting inflammation independent of direct actions on tumor cells provide novel insight into the clinical use of anti-estrogen drugs. Accordingly, ER antagonists that specifically block ERα could be used as adjuvant therapy in ER-positive breast cancer and other malignancies. MDSC induction during immunotherapy contributes to treatment failure in many tumors. The efficiency of anti-estrogen drugs in mitigating immunotherapeutic resistance requires further confirmation. In addition, MDSCs are reported to promote tumor angiogenesis, invasion and metastasis in cases of multiple cancers. Further studies are urgently needed to clarify the effects of anti-estrogen agents on tumor metastasis and angiogenesis.
Extensive studies have shown that estrogens are strongly implicated in gender differences in the prevalence of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), which shows a male-to-female ratio of 10:1. Estrogens have an important role in SLE and are related to metabolic changes and aromatase gene polymorphisms. 6 The role of MDSCs in SLE progression is rarely reported and remains uncertain. We previously demonstrated that both splenic granulocytic MDSCs and monocytic MDSCs are significantly expanded in mice with lupus and in high-disease-activity SLE patients. MDSCs have a crucial role in the pathogenesis of SLE by regulating the balance between T helper type 17 (Th17) and regulatory T cells. 7 It is important to determine whether estrogens are involved in the accumulation of MDSCs in SLE. To our knowledge, there is only one publication reporting that 17β-estradiol contributes to the accumulation of MDSCs in blood by promoting tumor necrosis factor α (TNF-α) secretion in vivo. 8 As a crucial contributor to the pathogenesis of SLE, serum levels of TNF-α are known to be significantly higher in SLE patients than in patients with non-autoimmune diseases. 9 The frequency of MDSCs in peripheral blood mononuclear cells and serum TNF-α levels are obviously higher in female SLE patients than in male SLE patients, confirming that estradiol levels are positively correlated with the presence of MDSCs in SLE patients. 8 However, how estrogens promote TNF-α secretion in SLE remains unknown. The association of estrogens with the pathogenesis of SLE also requires further clarification.
Although growing evidence indicates that MDSCs are involved in the pathogenesis of autoimmune diseases and cancers (Figure 1) , MDSC-associated expansion, activation and inhibitory functions remain controversial. Significantly Figure 1 Effects of estrogens on myeloid-derived suppressor cells in cancer and autoimmune diseases. Estrogens promote the development of estrogen receptor-positive cancers, but not estrogen receptor-negative cancers, by binding to the ER and activating signaling. Estrogens activate the STAT3 pathway in bone marrow myeloid precursors through the ER, leading to increased MDSCs with immunosuppressive activity on T cells in the tumor microenvironment. Estrogens also contribute to the accumulation of MDSCs in blood by promoting TNF-α secretion in SLE. MDSCs have a proinflammatory role in the pathogenesis of SLE by regulating the Th17 cell/Treg balance. Estrogens are strongly implicated in the gender differences in autoimmune diseases and may have an important role in MDSCs. EAE, experimental autoimmune encephalomyelitis; ER, estrogen receptor; MDSC, myeloid-derived suppressor cell; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; STAT3, signal transducer and activator of transcription factor 3; Th17, T helper type 17; TNF, tumor necrosis factor; Treg, regulatory T cell; T1D, type 1 diabetes mellitus.
increased MDSCs in the peripheral blood contribute to the progression of type 1 autoimmune diabetes and are associated with B-cell depletion. 10 Adoptive transfer of granulocytic MDSCs decreases the severity of joint inflammation in mouse models of collagen-induced rheumatoid arthritis. 11 It has also been reported that expanded MDSCs in arthritic mice and patients are positively correlated with disease severity and the inflammatory Th17 response. 12 In a transgenic mouse model of inflammatory bowel disease, repeated transfer of CD8+ T cells results in MDSC expansion. The transfer of isolated MDSCs inhibits disease progression and exerts a protective role in inflammatory bowel disease. 13 In experimental autoimmune encephalomyelitis, expanded CD11b+Gr-1+ MDSCs promote the differentiation of naive CD4+ T-cell precursors into Th17 cells, thereby exacerbating experimental autoimmune encephalomyelitis severity. 14 Another report showed that transferred granulocytic MDSCs reduce the expansion of autoreactive T cells and inhibit pathogenic Th1 and Th17 immune responses. 15 Owing to extraordinary heterogeneity and plasticity, MDSCs can exert either proinflammatory or suppressive effects in the pathogenesis of different autoimmune diseases. Accordingly, they express various phenotypes and regulate T-cell functions by different mechanisms. Multiple factors influence the differentiation and migration of MDSCs in autoimmune diseases. To use MDSCs in cellular therapy, further studies are essential to clarify their differentiation, phenotypes and functions.
Collectively, estrogens are strongly implicated in the gender differences in autoimmune diseases due to their mediation in the development and activation of immune cells. Additionally, MDSCs are significantly involved in the pathogenesis of autoimmune diseases, especially SLE. Further experiments will be helpful for the development of novel therapeutic strategies based on ER pathways and MDSCs.
